🎉 M&A multiples are live!
Check it out!

AN2 Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for AN2 Therapeutics and similar public comparables like Galapagos, Pharming, and Benevolent AI.

AN2 Therapeutics Overview

About AN2 Therapeutics

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.


Founded

2017

HQ

United States of America
Employees

22

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$55.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

AN2 Therapeutics Financials

AN2 Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, AN2 Therapeutics achieved revenue of n/a and an EBITDA of -$54.6M.

AN2 Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See AN2 Therapeutics valuation multiples based on analyst estimates

AN2 Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$69.6M -$54.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$41.0M -$64.7M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

AN2 Therapeutics Stock Performance

As of April 15, 2025, AN2 Therapeutics's stock price is $1.

AN2 Therapeutics has current market cap of $39.4M, and EV of -$55.8M.

See AN2 Therapeutics trading valuation data

AN2 Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$55.8M $39.4M XXX XXX XXX XXX $-1.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

AN2 Therapeutics Valuation Multiples

As of April 15, 2025, AN2 Therapeutics has market cap of $39.4M and EV of -$55.8M.

AN2 Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate AN2 Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for AN2 Therapeutics and 10K+ public comps

AN2 Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$55.8M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.0x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.1x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get AN2 Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

AN2 Therapeutics Valuation Multiples

AN2 Therapeutics's NTM/LTM revenue growth is n/a

AN2 Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.5M for the same period.

Over next 12 months, AN2 Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate AN2 Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for AN2 Therapeutics and other 10K+ public comps

AN2 Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -22% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.5M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

AN2 Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

AN2 Therapeutics M&A and Investment Activity

AN2 Therapeutics acquired  XXX companies to date.

Last acquisition by AN2 Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . AN2 Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by AN2 Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About AN2 Therapeutics

When was AN2 Therapeutics founded? AN2 Therapeutics was founded in 2017.
Where is AN2 Therapeutics headquartered? AN2 Therapeutics is headquartered in United States of America.
How many employees does AN2 Therapeutics have? As of today, AN2 Therapeutics has 22 employees.
Who is the CEO of AN2 Therapeutics? AN2 Therapeutics's CEO is Mr. Eric Easom.
Is AN2 Therapeutics publicy listed? Yes, AN2 Therapeutics is a public company listed on NAS.
What is the stock symbol of AN2 Therapeutics? AN2 Therapeutics trades under ANTX ticker.
When did AN2 Therapeutics go public? AN2 Therapeutics went public in 2022.
Who are competitors of AN2 Therapeutics? Similar companies to AN2 Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of AN2 Therapeutics? AN2 Therapeutics's current market cap is $39.4M
Is AN2 Therapeutics profitable? Yes, AN2 Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.